Global Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market - Overview
Ataxia refers to a disorder caused by the lack of coordination of muscle movements that impairs the ability to smoothly perform coordinated voluntary activities. Factors causing the disorder include cerebral and cerebellar disorders, peripheral nerve disorders, thalamic disorders, injuries to posterior spinal column, and basal ganglia disorders. The condition may affect eyes, the limbs, larynx, and pharynx. The rising prevalence of a variety of debilitating neurological disorders has increased the focus of the global healthcare fraternity on ways to completely treat these diseases. As a result, the frequency and extent of research activities is continuously widening in the field of progressive ataxia and weakness disorders.
This report presents an exhaustive account of the global market for the various treatment options available to treat syndromes of progressive ataxia and weakness disorders. The report examines the present state of market’s development, the scope of further improvements in terms of technological interventions and the drug candidates presently marketed in the market, and pipeline drugs. The report provides a detailed account of factors that will have a sizeable influence on the overall development of the market in over the forecast period. As such, the drivers, challenges, past and present trends, regulations, and other factors affecting the market’s potential course of growth are analyzed in the report.
Global Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market - Drivers and Restraints
Across the globe, treatment options for treating syndromes of progressive ataxia and weakness disorders are steadily increasing, with the field witnessing rising attention from research bodies and novel drug classes being introduced on a continued basis. Technological advancements in the field of pharmacology as a whole, stem cell therapy, and ataxia diagnosis are helping the market tread along a promising development path.
Although pharmacological treatments available in the market to stop or decelerate the progression of ataxia are limited at present and positive results have only been reported in few clinical trials, the use of amantadine has been found useful in increasing energy levels and slowing down the progression to a certain level. The use of the drug candidate baclofen in small doses is considered to be useful in reducing leg spasticity.
Apart from developments in the field of new drug varieties, the market is also being enriched due to the many new developments in the areas such as gene mutation and protein misfolding. However, the market’s growth and profitability are impeded to a certain extent owing to the recent expirations of popular drugs.
Global Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market - Segmentation
The global market for the treatment of syndromes of progressive ataxia and weakness disorders is primarily segmented in the report in three broads segments: key dysfunction or disorders, treatment technology, and geography. Dysfunction or disorders sub-segment include most prevalent ataxia conditions such as Friedreich's ataxia, hereditary neuropathies, Machado Joseph disease, progressive bulbar palsy, and multiple sclerosis. On the basis of treatment technology, the market is segmented into monoclonal antibody and small molecule technologies. On the basis of geography, the market is segmented into regions such as North America, Europe, Asia Pacific, and Middle East and Africa.
Global Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market - Competitive Dynamics
The report gives a detailed overview of the competitive and vendor landscape of the market with the help of detailed business profiles of some of the key vendors operating in the market. The report also includes a comprehensive analysis of recent developments in the market in terms of technology and drug candidates and details about activities such as mergers, acquisitions, and consolidations. Porter’s five forces analysis of the market gives detailed insights into the nature of competition and attractiveness of various sectors of the market.
Some of the key vendors contributing through research and products to the overall development of the field of treatment of syndromes of progressive ataxia and weakness disorders are Acorda Therapeutics Inc., Cadila Healthcare Ltd., American Regent Inc., Dr. Reddy Laboratories, Sanofi, Baxter International Inc., Pfizer Inc., Novartis AG, Abbott Laboratories, Bristol-Myers Squibb, Biogen Idec., Eli Lilly and Company, and Roche Holding Ltd.
Major regions analyzed under this research report are:
- North America
- Asia Pacific
- Rest of the World
This report gives you access to decisive data such as:
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for the coming years
Key highlights of this report
- Overview of key market forces propelling and restraining market growth
- Up-to-date analyses of market trends and technological improvements
- Pin-point analyses of market competition dynamics to offer you a competitive edge
- An analysis of strategies of major competitors
- An array of graphics and SWOT analysis of major industry segments
- Detailed analyses of industry trends
- A well-defined technological growth map with an impact-analysis
- Offers a clear understanding of the competitive landscape and key product segments